New Jersey S3098 mandates health insurers to cover biomarker precision medical testing.
New Jersey S3098 requires health insurers to provide coverage for biomarker precision medical testing. This includes various types of tests such as single-analyte tests, multiplex panel tests, and whole exome sequencing. The bill mandates that coverage be provided for diagnosis, treatment, management, or monitoring of diseases or conditions when supported by medical and scientific evidence. This includes FDA-approved tests, indicated tests for FDA-approved drugs, and warnings on FDA-approved drug labels.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.